Monthly pulse methylprednisolone vs. oral prednisolone in treatment of thyroid ophthalmopathy: An open label randomized controlled trial

Department of Endocrinology and Metabolism0 个研究点目标入组 50 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patients of moderately severe Thyroid associated orbitopathy (TAO) with moderate activity (Clinical activity score >2)were included.
•Moderate to severe TAO was defined as marked soft tissue swelling (2c by NOSPECS), and/or proptosis (>=18mm in females; >=20mm in males; 3a or more by NOSPECS), and/or inconstant/constant diplopia in primary or reading position (4b by NOSPECS), and/or punctuate staining of cornea, without any optic nerve involvement, as suggested by European Group on Gravesâ?? Orbitopathy

•Patients with mild TAO, dysthyroid optic neuropathy (DON) and severe sight-threatening TAO were excluded.Patients were excluded who had received steroids, radiotherapy, immunosuppressive therapy or surgery for TAO. Patients with comorbidities making glucocorticoid administration difficult (uncontrolled hypertension, uncontrolled diabetes, tuberculosis, immune-compromised state, chronic liver disease, viral hepatitis, tuberculosis) were excluded.

发起方

Department of Endocrinology and Metabolism